These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 18754430

  • 1. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ, Qiu Q, Yang XY, Xu HS, Ye YJ, Zhan ZP, Lian F, Chen DY.
    Zhonghua Yi Xue Za Zhi; 2008 Apr 15; 88(15):1009-11. PubMed ID: 18754430
    [Abstract] [Full Text] [Related]

  • 2. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ.
    Arthritis Rheum; 2005 Sep 15; 52(9):2761-7. PubMed ID: 16142702
    [Abstract] [Full Text] [Related]

  • 3. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K, Wildt L, Kalden JR, Manger B.
    Autoimmun Rev; 2006 Apr 15; 5(4):269-72. PubMed ID: 16697968
    [Abstract] [Full Text] [Related]

  • 4. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC.
    J Rheumatol; 2002 Dec 15; 29(12):2571-6. PubMed ID: 12465154
    [Abstract] [Full Text] [Related]

  • 5. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug 15; 42(8):546-50. PubMed ID: 17983495
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M.
    Lupus; 2000 Aug 15; 9(6):401-5. PubMed ID: 10981642
    [Abstract] [Full Text] [Related]

  • 8. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
    Blumenfeld Z.
    Minerva Endocrinol; 2007 Mar 15; 32(1):23-34. PubMed ID: 17353864
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC, Lau CS, Wong RW.
    Arthritis Rheum; 1998 May 15; 41(5):831-7. PubMed ID: 9588734
    [Abstract] [Full Text] [Related]

  • 10. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
    Sinha R, Dionne JM.
    Arch Dis Child; 2008 May 15; 93(5):444-5. PubMed ID: 17908713
    [No Abstract] [Full Text] [Related]

  • 11. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC, Wong RW, Lau CS.
    Arthritis Rheum; 1999 Jun 15; 42(6):1274-80. PubMed ID: 10366122
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
    Yang XY, Zhu X, Liang LQ, Zhan ZP, Ye YJ.
    Zhonghua Yi Xue Za Zhi; 2005 Apr 13; 85(14):960-2. PubMed ID: 16061002
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
    Petri M, Jones RJ, Brodsky RA.
    Arthritis Rheum; 2003 Jan 13; 48(1):166-73. PubMed ID: 12528116
    [Abstract] [Full Text] [Related]

  • 16. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
    Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Murakami N, Kitajima M, Kawakami A.
    Int J Rheum Dis; 2018 Jun 13; 21(6):1287-1292. PubMed ID: 29879312
    [Abstract] [Full Text] [Related]

  • 17. [Protective effect of estrogen against chemotherapy-induced ovarian damage in rats].
    Han LP, He YL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 May 13; 29(5):872-5. PubMed ID: 19460696
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy.
    Franke HR, Smit WM, Vermes I.
    Gynecol Endocrinol; 2005 May 13; 20(5):274-8. PubMed ID: 16019373
    [Abstract] [Full Text] [Related]

  • 20. Intravenous cyclophosphamide for lupus nephritis in Thai children.
    Vachvanichsanong P, Dissaneewate P, Winn T.
    Scand J Rheumatol; 2004 May 13; 33(5):339-42. PubMed ID: 15513684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.